Quoted, “A Big Announcement Thursday Could Mean Big Things for Seniors — And the Election,” Huffington Post, August 14, 2024.
Quoted, “Sanders looks to harness outrage on drug prices,” Axios Pro, February 6, 2024.
Quoted, “Biden FDA Approves Florida Plan to Import Drugs From Canada,” Bloomberg Law, January 5, 2024.
Quoted, “How a Republican president could affect Medicare drug negotiations,” Axios, September 1, 2023.
Quoted, “Medicare Negotiation List Surprises Highlight The Importance Of Current Spending Data,” Pink Sheet, August 30, 2023.
Quoted, “HHS Fans Legal Flames With Medicare Drug Negotiation Picks,” Law360, August 29, 2023.
Quoted, “Senate Finance Committee PBM Reform Results In ‘Decimal Dust’ Of Savings,” Pink Sheet, July 25, 2023.
Quoted, “FTC Expands PBM Probe To Group Purchasing Organizations,” Pink Sheet, May 18, 2023.
Quoted, “A Level Playing Field? Medicare Tries To Balance Transparency, Confidentiality With Drug Price Negotiations,” Pink Sheet, April 10, 2023.
Quoted, “Congressional Pressure Mounts On PBMs, But Skepticism Remains About Near-Term Action,” Pink Sheet, March 1, 2023.
Quoted, “Medicare Will Pick Drugs For Negotiation Based On Gross Sales, Disadvantaging Highly-Rebated Products,” Pink Sheet, January 12, 2023.
Quoted, “The way Medicare will negotiate down prescription drug prices takes shape,” MarketWatch, January 11, 2023.
Quoted, “Experts talk IRA impacts as CMS announces it will publish first 10 drugs up for negotiation in September,” Endpoints News, January 11, 2023.
Quoted, “What pharma could gain — or lose — from the midterms,” PharmaVoice, November 7, 2022.
Quoted, “Pharma can't give up on Dems as it tries to weaken drug price law,” Axios, October 5, 2022.
Author, “Implementing The Drug Negotiation Provisions Of The IRA: Considerations For CMS,” Health Affairs, September 30, 2022.
Quoted, “FTC And PBMs: Support For Investigation Building But Outcome May Ultimately Disappoint Critics,” Pink Sheet, May 25, 2022.
Quoted, “Biden Wants Congress To Set Sights On Cutting Drug Prices,” Law360, August 12, 2021.
Quoted, “Beyond Aduhelm: OIG Review Will Put FDA’s Entire Accelerated Approval Program Under Microscope,” Pink Sheet, August 4, 2021.
Quoted, “Biden Executive Order Targets Competition to Lower Drug Prices,” MedPage Today, July 12, 2021.
Co-author, “What’s Ahead for Health Policy in 2021,” RamaOnHealthcare, February 3, 2021.
Author, “FDA Calls States’ Bluffs on Drug Importation,” Stat, February 18, 2020.
Author, “Rush to End Drug Rebates May Be Bad for Patients, Payers, and Pharma,” Stat, September 7, 2018.
Author, “IPAB RIP,” Health Affairs blog, February 22, 2018.
Co-author, “The Future of Essential Health Benefits,” Health Affairs blog, February 14, 2017.
Co-author, “Supporting Informed Decision-Making in the Health Insurance Marketplace: A Progress Report,” National Partnership for Women and Families, February 2015.
Co-author, “Five Megatrends Driving the Seismic Shift in Healthcare: How Should Pharma Respond to Succeed in a Transformed Market?” Manatt Health Solutions, July 2014.
Author, “Medicare Part D Proposed Rule: Where Did Things Go Wrong?” Health Affairs blog, March 6, 2014.
Co-author, “Specialty Pharmaceuticals,” Health Affairs, November 25, 2013.
Co-author, "Sequestration and Medicare: The Two Percent Solution?" BNA's Medicare Report, September 16, 2011.
Co-author, "The Proposed ACO Program: Issues for the Life Sciences Industry," BNA's Life Sciences Law & Industry Report, May 6, 2011.
Co-author, “Affordable Care Act Provisions in the 2011 Medicare Physician Fee Rule,” BNA’s Medicare Report, July 23, 2010.